Get the Stockscreener App
16.85
786.84%
14.95
After Hours:
17.70
0.85
+5.04%
Atyr Pharma Inc stock is traded at $16.85, with a volume of 4.97M.
It is up +786.84% in the last 24 hours and up +786.84% over the past month.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. It is also developing ATYR1940, a therapeutic candidate based on a protein naturally secreted from muscle for the treatment of facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and duchenne muscular dystrophy. aTyr Pharma, Inc. was founded in 2005 and is headquartered in San Diego, California.
See More
Previous Close:
$1.90
Open:
$19
24h Volume:
4.97M
Relative Volume:
66.00
Market Cap:
$131.12M
Revenue:
-
Net Income/Loss:
$-50.39M
P/E Ratio:
-17.55
EPS:
-0.96
Net Cash Flow:
$-37.44M
1W Performance:
+786.84%
1M Performance:
+786.84%
6M Performance:
+786.84%
1Y Performance:
+786.84%
1-Day Range:
$15.51
$19.00
1-Week Range:
$15.51
$19.00
52-Week Range:
$15.51
$19.00
Atyr Pharma Inc Stock (LIFE) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
858-731-8389
Address
3545 John Hopkins Court, Suite 250, San Diego, CA
Compare LIFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIFE
Atyr Pharma Inc
|
16.85 | 131.12M | 0 | -50.39M | -37.44M | -0.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.68 | 121.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.44 | 78.94B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
847.72 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
346.79 | 46.18B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Atyr Pharma Inc Stock (LIFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-15-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (LIFE) Latest News
Is aTyr Pharma Inc. stock forming a triangle patternJuly 2025 Catalysts & Safe Capital Preservation Plans - mfd.ru
Is aTyr Pharma Inc backed by strong institutional buyingJuly 2025 WrapUp & Reliable Intraday Trade Plans - baoquankhu1.vn
Aug Update: Does aTyr Pharma Inc. have pricing powerMarket Risk Analysis & Fast Gain Swing Alerts - baoquankhu1.vn
aTyr Pharma, Inc. (NASDAQ:ATYR) Sees Significant Drop in Short Interest - MarketBeat
Fed Meeting: Is Focus Universal Inc currently under institutional pressureWatch List & Low Risk Entry Point Guides - baoquankhu1.vn
Volume Recap: What drives aTyr Pharma Incs stock priceWeekly Stock Recap & AI Powered Market Trend Analysis - baoquankhu1.vn
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
How aTyr Pharma Inc. stock benefits from tech adoptionMarket Growth Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Will aTyr Pharma Inc. stock outperform growth indexesTrade Entry Report & Free Technical Confirmation Trade Alerts - ulpravda.ru
Will aTyr Pharma Inc. stock split attract more investorsJuly 2025 Summary & Long-Term Growth Plans - ulpravda.ru
Aug Chart Watch: How aTyr Pharma Inc. stock benefits from tech adoptionWeekly Stock Recap & Intraday High Probability Alerts - ulpravda.ru
Can aTyr Pharma Inc. (471A) stock sustain breakout momentumDay Trade & Safe Capital Allocation Plans - ulpravda.ru
Aug EndMonth: Will aTyr Pharma Inc. stock split attract more investorsJuly 2025 WrapUp & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
How strong is aTyr Pharma Inc. stock revenue growthPortfolio Return Report & Low Risk Investment Opportunities - ulpravda.ru
aTyr Pharma, Inc. (ATYR) Stock Analysis: Unveiling a 483% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
aTyr Pharma (NASDAQ:ATYR) Stock Price Up 3.1%Still a Buy? - MarketBeat
Will aTyr Pharma Inc. stock attract ESG investorsStock Watchlist Updates & Exceptional Trading Strategies - ulpravda.ru
Will aTyr Pharma Inc. (471A) stock beat Nasdaq index returns2026 world cup usa national team quarterfinals playmakers high defensive line expert forecast preview - Улправда
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR)Join by December 8, 2025Contact Levi & Korsinsky - The National Law Review
Is aTyr Pharma Inc. stock affected by interest rate hikesJuly 2025 Snapshot & Free Safe Entry Trade Signal Reports - Улправда
How aTyr Pharma Inc. stock reacts to inflationary pressures2025 Buyback Activity & Fast Momentum Stock Entry Tips - Улправда
ATyr Pharma, Inc.(NasdaqCM:ATYR) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Will aTyr Pharma Inc. stock remain a Wall Street favorite2025 Top Gainers & Technical Confirmation Alerts - Улправда
Winners Losers: Will aTyr Pharma Inc. stock remain a Wall Street favoriteWeekly Investment Recap & Accurate Entry/Exit Alerts - Улправда
Why analysts raise outlook for aTyr Pharma Inc. (471A) stockExit Point & AI Forecast for Swing Trade Picks - DonanımHaber
Aug Fed Impact: How aTyr Pharma Inc. stock reacts to inflationary pressures2025 Growth vs Value & Daily Market Momentum Tracking - Улправда
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders - marketscreener.com
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Hold” by Brokerages - Defense World
Healthy Upside Potential: Atyr Pharma Inc (ATYR) - Setenews
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - Morningstar
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Le - GuruFocus
Investors SueWallSt Over aTyr Pharma, Inc. Stock DropContact Levi & Korsinsky to Join - Louisiana First News
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - galvnews.com
ATYR DEADLINE ALERT: Hagens Berman Alerts aTyr Pharma - GlobeNewswire
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc - GuruFocus
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
ATyr Pharma, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsATYR - marketscreener.com
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securi - GuruFocus
Levi & Korsinsky Notifies aTyr Pharma, Inc. (ATYR) InvestorsLead Plaintiff Deadline on December 8, 2025 - ACCESS Newswire
ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - TMX Newsfile
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile
ATYR CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, - GlobeNewswire
ATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, - GlobeNewswire
Atyr Pharma Inc Stock (LIFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):